Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deflazacort + perindopril
- Development stage
- Preclinical
- Lead developer
- Marathon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of deflazacort, a corticosteroid prodrug, and perindopril, an ACE inhibitor. This combination is used in the management of Duchenne Muscular Dystrophy (DMD), particularly to address both muscle deterioration and cardiomyopathy associated with the condition. Deflazacort helps preserve skeletal and cardiac muscle function while perindopril may help prevent or delay the onset of cardiomyopathy in DMD patients.
02
Targets
GR (Glucocorticoid receptor)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on deflazacort + perindopril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deflazacort + perindopril.